[Financial Highlights](index=1&type=section&id=%E8%B2%A1%E5%8B%99%E6%91%98%E8%A6%81) During the reporting period, the company achieved significant growth in revenue, gross profit, R&D expenses, and net profit attributable to parent company shareholders, but the board does not recommend an interim dividend Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB million) | June 30, 2024 (RMB million) | Year-over-year growth rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 329.7 | 249.1 | 32.4 | | Gross Profit | 284.3 | 226.7 | 25.4 | | R&D Expenses | 25.4 | 21.7 | 17.0 | | Net Profit Attributable to Parent Company Shareholders | 182.0 | 140.2 | 29.8 | - The Board does not recommend an interim dividend for the six months ended June 30, 2025 (for the six months ended June 30, 2024: nil)[5](index=5&type=chunk) [Management Discussion and Analysis](index=2&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%A4%E8%A8%8E%E8%AB%96%E8%88%87%E5%88%86%E6%9E%90) During the reporting period, the company maintained strong business momentum with stable revenue growth, continuous innovation in cardiovascular interventional devices, particularly in biodegradable technology and structural heart disease treatment, and active expansion in domestic and international markets [Business Review](index=2&type=section&id=%E6%A5%AD%E5%8B%99%E5%9B%9E%E9%A1%A7) The company specializes in R&D, production, and commercialization of cardiovascular interventional devices, offering a broad product portfolio including congenital heart disease occluders, PFO and LAA occluders, heart valves, mechanical circulatory support, and access products, with many innovative products successfully commercialized or in clinical stages [Overall Operating Performance](index=5&type=section&id=%E6%95%B4%E9%AB%94%E7%B6%93%E7%87%9F%E6%A5%AD%E7%B8%BE) During the reporting period, the company achieved double-digit growth in revenue and net profit, significantly increased operating cash flow, and maintained steady growth in total assets Financial Highlights for the Six Months Ended June 30, 2025 | Indicator | June 30, 2025 (RMB million) | June 30, 2024 (RMB million) | Year-over-year growth rate (%) | | :--- | :--- | :--- | :--- | | Revenue | 329.7 | 249.1 | 32.4 | | Net Profit Attributable to Parent Company Shareholders | 182.0 | 140.2 | 29.8 | | Net Cash Generated from Operating Activities | 166.8 | 103.5 | 61.2 | | Total Assets (end of period) | 2,279.1 | 2,083.0 (beginning of reporting period) | 9.4 | | Net Assets (end of period) | 1,973.2 | 1,997.0 (beginning of reporting period) | -1.2 | [Congenital Heart Disease Occluder Products](index=2&type=section&id=%E5%85%88%E5%A4%A9%E6%80%A7%E5%BF%83%E8%87%9F%E7%97%85%E5%B0%81%E5%A0%B5%E5%99%A8%E7%94%A2%E5%93%81) The company maintains a leading position in congenital heart disease occluders, with third-generation oxide film and fourth-generation biodegradable occluder series successfully commercialized, becoming a cornerstone of business growth and embodying the "intervention without implant" philosophy - As of the date of this announcement, the Company has a total of **30** listed occluders, heart valve and accessory products, **4** products under registration review and preparation, and **28** pipeline products including occluders, heart valve and surgical accessories, and mechanical circulatory support at various R&D stages[6](index=6&type=chunk) - The fourth-generation MemoSorb® biodegradable atrial septal defect occluder product obtained the medical device registration certificate from the NMPA in August 2024 and has been rapidly commercialized[11](index=11&type=chunk) - Adhering to the technical concept of "intervention without implant," the Group will continue to promote the R&D and promotion of biodegradable materials[11](index=11&type=chunk) [PFO and LAA Occluder Products](index=6&type=section&id=%E5%8D%B5%E5%9C%93%E5%AD%94%E6%9C%AA%E9%96%89%E5%8F%8A%E5%B7%A6%E5%BF%83%E8%80%B3%E5%B0%81%E5%A0%B5%E5%99%A8%E7%94%A2%E5%93%81) First-generation cardiogenic stroke prevention products have been commercialized, with third-generation MemoSorb® biodegradable PFO occluders achieving over **RMB 200 million** in sales since launch, second-generation oxide film PFO occluders entering the registration application stage, and biodegradable LAA occluders entering multi-center clinical trials - The third-generation MemoSorb® biodegradable PFO occluder was approved for market in September 2023, with cumulative sales exceeding **RMB 200 million** as of June 30, 2025[12](index=12&type=chunk) - The second-generation oxide film PFO occluder has completed clinical follow-up and entered the registration application stage, with NMPA registration submission expected in **Q3 2025**[12](index=12&type=chunk) - The Bio-Lefort® biodegradable LAA occluder pipeline product has officially entered the multi-center clinical trial enrollment phase[12](index=12&type=chunk) [Aortic and Peripheral Occluder Devices](index=7&type=section&id=%E4%B8%BB%E5%8B%95%E8%84%88%E5%8F%8A%E5%A4%96%E5%91%A8%E5%B0%81%E5%A0%B5%E5%99%A8%E6%A2%B0) The company is strategically developing biodegradable aortic occluders and aortic embolization occluders in the aortic and peripheral fields, with both global innovative products having entered clinical trial stages, poised to address international challenges and offering promising market prospects - Both biodegradable aortic occluders and aortic embolization occluders have completed type testing and animal experiments, entering the clinical trial stage[13](index=13&type=chunk) - Currently, no targeted therapeutic devices for aortic dissection rupture and post-aortic aneurysm repair type II endoleak have been commercialized, making both of the Group's products global innovations[13](index=13&type=chunk) [Heart Valve Pipeline Products](index=7&type=section&id=%E5%BF%83%E8%87%9F%E7%93%A3%E8%86%9C%E5%9C%A8%E7%A0%94%E7%94%A2%E5%93%81) The ScienCrown® transcatheter aortic valve system was commercialized in early 2025, entering over **70** clinical centers in China, and the company is actively developing new products for aortic regurgitation, mitral valve repair, and replacement - The ScienCrown® transcatheter aortic valve system was officially commercialized in early 2025, having entered over **70** clinical centers in China for implantation[14](index=14&type=chunk) - A transcatheter aortic valve system for patients with isolated aortic regurgitation is currently under development, having completed animal experiments and type testing, with clinical trials planned for late 2025[14](index=14&type=chunk)[15](index=15&type=chunk) - The transapical mitral valve clip system is undergoing its second phase of clinical trials, with registration application to the NMPA expected to be postponed until 2026[15](index=15&type=chunk) [Mechanical Circulatory Support Products](index=8&type=section&id=%E6%A9%9F%E6%A2%B0%E5%BE%AA%E7%92%B0%E8%BC%94%E5%8A%A9%E7%94%A2%E5%93%81) The company has entered the mechanical circulatory support (MCS) device field, with a product line covering short-term and long-term ventricular assist systems, and multiple products in preclinical or type testing stages, aiming to become a core participant in this domain - The Company has entered the mechanical circulatory support (MCS) device field, with these devices designed to provide temporary or long-term support for patients requiring cardiac assistance[16](index=16&type=chunk) - The transcatheter left ventricular assist system for left ventricular support is in the preclinical type testing stage, with batch animal experiments already initiated[16](index=16&type=chunk) - The Company is one of the earliest pioneers in the domestic MCS field and is confident in becoming one of the most core and valuable participants in this area[16](index=16&type=chunk) [Access Products](index=8&type=section&id=%E9%80%9A%E8%B7%AF%E9%A1%9E%E7%94%A2%E5%93%81) The company boasts a rich pipeline of access products, with RF-Lance® radiofrequency puncture devices and needles approved for market, biodegradable LAA occluder delivery systems launched, and multiple valve surgery accessories (such as aortic valve balloon dilation catheters) approved or in clinical/registration stages - The RF-Lance® radiofrequency puncture device and RF-Lance® disposable radiofrequency atrial septal puncture needle were approved for market

格隆汇8月12日丨心泰医疗(02291.HK)宣布，本公司将于2025年8月22日（星期五）举行董事会会议，藉 以（其中包括）考虑及批准本公司及其附属公司截至2025年6月30日止六个月的未经审核中期业绩及其 发布，并考虑建议派发中期股息（如有）。 ...

（股份代號：2291） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 樂普心泰醫療科技（上海）股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2025年8月22日（星期五）舉行董事會會議，藉以（其中包 括）考慮及批准本公司及其附屬公司截至2025年6月30日止六個月的未經審核中期 業績及其發佈，並考慮建議派發中期股息（如有）。 * 本公司註冊為香港法例第622章《公司條例》所定義的非香港公司，以其中文名稱及英文名 稱「LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.」註冊。 承董事會命 樂普心泰醫療科技（上海）股份有限公司 陳娟女士 董事長兼執行董事 中 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2 ...

消息上，为支持药品和医疗器械创新发展，国家医保局日前制定新上市药品首发价格机制，新增了100 多项与医疗新技术相关的价格项目，促进高端医疗设备的临床转化应用。 中信建投研报称，港股医疗器械公司整体创新性较强，多家企业即将步入扭亏为盈或业绩快速释放的阶 段。今年以来，有创新产品上市、技术突破实现license-out可能的催化，以及账上现金丰富、业绩快速 释放、估值低位的部分18A器械公司，年初至今有翻倍以上的涨幅；部分业绩高增长的低估值龙头器械 公司年初至今亦有较好表现。(格隆汇) 心泰医疗(2291.HK)盘中一度涨近8%，高见27.4港元创4月底以来新高，近一个月累计升幅达30%，总市 值93亿港元。 公司是稳健盈利的港股创新医疗器械企业。根据弗若斯特沙利文统计，就2021年的销售收入而言，心泰 医疗是中国最大的先天性心脏病封堵器制造商（市场份额为38%）。 ...

Group 1 - The article provides a list of companies listed on the Hong Kong stock market along with their dividend distribution dates and shareholder meeting dates [1][4][5] - Notable companies mentioned include China Railway, Green Town China, and Budweiser APAC, which are scheduled for dividend payments [4][5] - The document outlines various companies' actions regarding capital increases and dividend distributions, indicating ongoing corporate activities in the market [4][5]

[Company Announcement: Proposed Appointment of Supervisor and Supplemental Announcement Regarding Annual Reports](index=1&type=section&id=%E5%85%AC%E5%8F%B8%E5%85%AC%E5%91%8A%EF%BC%9A%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B%E5%8F%8A%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) This announcement details the proposed appointment of a new supervisor and clarifies supervisor remuneration in annual reports [Proposed Appointment of Supervisor](index=1&type=section&id=%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B) The company proposes Ms. Wang Yong as shareholder representative supervisor and chairperson, pending shareholder approval - The company's board of supervisors recommends appointing Ms. Wang Yong as a supervisor and chairperson of the second board of supervisors[3](index=3&type=chunk) - This appointment is subject to approval by an ordinary resolution at the general meeting of shareholders[3](index=3&type=chunk)[8](index=8&type=chunk) - As a shareholder representative supervisor, Ms. Wang will not receive any remuneration from the company[7](index=7&type=chunk) [Supervisor Candidate Background: Ms. Wang Yong](index=1&type=section&id=%E7%9B%A3%E4%BA%8B%E5%80%99%E9%81%B8%E4%BA%BA%E7%9A%84%E8%83%8C%E6%99%AF) Ms. Wang Yong, 52, CFO of Lepu Medical, possesses CPA qualifications and audit experience Key Background Information | Item | Content | | :--- | :--- | | Age | 52 | | Nationality | China | | Current Key Positions | CFO, Senior Deputy General Manager at Lepu Medical (Controlling Shareholder, 300003.SZ) | | Past Key Experience | Senior Audit Manager, Audit Department, PwC Zhong Tian CPAs Beijing Branch (1996-2007) | | Professional Qualifications | Certified Public Accountant (obtained 2001) | Shareholding Information | Company Held | Capacity | Shares/Percentage | | :--- | :--- | :--- | | The Company | Via Employee Stock Ownership Platform | 147,221 shares (approx. 0.04%) | | Lepu Medical | Beneficial Owner | 191,700 shares (approx. 0.01%) | | Beijing Lepu Diagnostics | Via Employee Stock Ownership Platform | 383,955 shares (approx. 0.10%) | - Ms. Wang holds director or supervisor positions in several affiliated or non-affiliated companies, including Sichuan Ruijian Medical, Shanghai Lepu Yunzhi, and Sino-American Huashitong[4](index=4&type=chunk) [Supplemental Announcement Regarding Annual Reports](index=3&type=section&id=%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) The company clarifies that total remuneration paid to all supervisors for fiscal years 2022-2024 was zero - This announcement provides supplementary information for the company's 2022, 2023, and 2024 annual reports[9](index=9&type=chunk) Total Remuneration Paid to All Supervisors | Fiscal Year | Total Remuneration Paid to All Supervisors | | :--- | :--- | | 2022 | Zero | | 2023 | Zero | | 2024 | Zero | - The disclosed total remuneration of zero covers all items, including fees, basic salary, housing allowances, in-kind benefits, and bonuses[9](index=9&type=chunk)

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]

Core Viewpoint - The article highlights the successful commercialization and clinical application of the ScienCrown transcatheter aortic valve replacement (TAVR) system developed by Lepu Medical Technology, marking a significant advancement in the treatment of aortic stenosis patients in China [2][5][10]. Company Overview - Lepu Medical Technology (Shanghai) Co., Ltd. is a leading innovator in the field of interventional medical devices for structural heart diseases, supported by the Shanghai Biomedical Investment Fund. The company went public on November 8, 2022, on the Hong Kong Stock Exchange under the stock code 02291.HK [17]. - The company focuses on the research, development, production, and marketing of interventional medical devices, with over 40 products listed and in development, covering congenital heart disease, stroke prevention, and valve treatment solutions [17]. Product Introduction - The ScienCrown TAVR system is the world's first and only self-expanding short valve product with balloon-expandable advantages, designed to address existing challenges in TAVR procedures [4][12]. - The product features 100% full release and retrieval capabilities, dual access routes, and innovative designs that significantly enhance clinical practice [4][12][15]. Clinical Application - The first commercial implantations of the ScienCrown valve have been successfully conducted in multiple clinical centers across China, demonstrating its effectiveness and safety [5][7]. - Clinical trial results indicate a procedural success rate of approximately 99.2% and a device success rate of about 98.4%, with low rates of paravalvular leak and no severe leaks reported [7][10]. Market Context - Aortic valve disease, particularly aortic stenosis (AS), is a common cardiovascular issue, especially among the elderly, with a prevalence of approximately 11.5% in patients over 60 years old [8][10]. - The number of patients with aortic stenosis and aortic regurgitation in China is projected to reach 9.3 million by 2025, with a compound annual growth rate of 2.6% from 2022 to 2025 [10].

Group 1: Hong Kong Stock Market Performance - The Hang Seng Index rose by 1.36%, gaining 297 points to close at 22,206 points, while the Hang Seng Tech Index increased by 1.87% [1] - The early trading volume in the Hong Kong stock market reached HKD 116.4 billion [1] Group 2: Real Estate Sector - Foreign institutions are optimistic about the recovery of the Chinese real estate sector, with Citigroup strategists urging investors to increase their holdings in Chinese real estate stocks due to expected improvements in profitability from policy support and better management practices [1] - Kwan Hung Holdings surged over 43%, while other notable gains included Rongxin China up 17%, Greentown China up 5%, CIFI Holdings up 7.88%, Sunac China up 4.22%, and Longfor Group up 6.74% [1] Group 3: AI Medical Sector - AI medical concept stocks saw an uptick as seven departments jointly promoted AI empowerment across the pharmaceutical industry, with institutions optimistic about the accelerated trend in the AI medical industry [1] - Notable stock performances included iFlytek Medical Technology up 7.2%, Yidu Tech up 5.35%, Crystal Tech Holdings up 4.69%, and MicroPort Scientific up 4.07% [1] Group 4: Other Notable Stocks - Horizon Robotics rose over 7% following a strategic partnership with Bosch to develop an upgraded version of Bosch's advanced driver assistance system [2] - KPB Medical surged over 14%, with a cumulative increase of over 95% this week after its core product was approved for sale in China [3] - Xintai Medical increased by 3.88%, although the company indicated uncertainty regarding its sales growth targets [4] - Minmetals Resources rose over 5%, reporting a 76% year-on-year increase in copper production for the first quarter, with potential adjustments to production guidance [5] - Beike-W increased by 4.88%, as the real estate fundamentals became clearer, with institutions suggesting its stock price is entering a value range [6] - Global New Materials International saw a sharp rise of over 20% before settling at a 4% increase after acquiring Merck's global performance solutions business [7]